[go: up one dir, main page]

MX2015007678A - Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. - Google Patents

Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.

Info

Publication number
MX2015007678A
MX2015007678A MX2015007678A MX2015007678A MX2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
transmucosal delivery
percent
weight
provides
Prior art date
Application number
MX2015007678A
Other languages
English (en)
Inventor
Ursula Geister
Stephan Schweizer
Martina Buerger
Ralph Stefan
Gerald Huber
Tanja Pries
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015007678A publication Critical patent/MX2015007678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una tableta oral que comprende acetato de glatirámero en una cantidad de aproximadamente (10) por ciento a aproximadamente (60) por ciento en peso y uno o más agentes gelificantes en una cantidad total de hasta aproximadamente (90) por ciento en peso. La presente invención también proporciona un método de liberación de acetato de glatirámero a través de una membrana bucal que comprende administrar oralmente una tableta de cualquiera de las modalidades.
MX2015007678A 2012-12-21 2013-12-20 Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. MX2015007678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
MX2015007678A true MX2015007678A (es) 2015-09-07

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007678A MX2015007678A (es) 2012-12-21 2013-12-20 Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.

Country Status (15)

Country Link
US (1) US20160193276A1 (es)
EP (1) EP2934492A4 (es)
JP (1) JP2016503803A (es)
KR (1) KR20150111918A (es)
CN (1) CN104869983A (es)
AU (1) AU2013361053A1 (es)
BR (1) BR112015014095A2 (es)
CA (1) CA2895359A1 (es)
EA (1) EA201591188A1 (es)
HK (2) HK1214134A1 (es)
IL (1) IL239280A0 (es)
MX (1) MX2015007678A (es)
SG (1) SG11201504422XA (es)
WO (1) WO2014100639A1 (es)
ZA (1) ZA201505049B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008573A2 (pt) 2010-10-11 2016-07-12 Teva Pharma citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
CN103957705A (zh) 2011-10-10 2014-07-30 泰华制药工业有限公司 适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
TWI781921B (zh) * 2016-02-12 2022-11-01 日商特一華製藥股份有限公司 乾式造粒物及含有該乾式造粒物之固形製劑以及其製造方法
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3846901A (en) * 2000-02-18 2001-08-27 Yeda Res & Dev Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
US8048449B2 (en) * 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
ES2585902T3 (es) * 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
EA201591188A1 (ru) 2016-04-29
CN104869983A (zh) 2015-08-26
HK1214134A1 (zh) 2016-07-22
EP2934492A1 (en) 2015-10-28
HK1214523A1 (zh) 2016-07-29
KR20150111918A (ko) 2015-10-06
US20160193276A1 (en) 2016-07-07
AU2013361053A1 (en) 2015-07-30
BR112015014095A2 (pt) 2017-07-11
ZA201505049B (en) 2016-10-26
IL239280A0 (en) 2015-07-30
EP2934492A4 (en) 2016-08-17
JP2016503803A (ja) 2016-02-08
SG11201504422XA (en) 2015-07-30
WO2014100639A1 (en) 2014-06-26
CA2895359A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY181159A (en) Sublingual and buccal film compositions
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
IN2014CN03214A (es)
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
PH12013502325A1 (en) Drug delivery system
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015007794A (es) Suministro transmucosal de acetato de glatiramer mediante parches orales.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
IN2014DN09240A (es)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
IN2013CH01615A (es)
TR200805337A2 (tr) Valsartan etkin maddesini içeren yeni oral farmasötik formülasyonlar